[SCHEDULE 13D/A] ABVC BioPharma, Inc. SEC Filing

Rhea-AI Filing Summary

Paychex Inc. (PAYX) – Form 5 Annual Statement of Changes in Beneficial Ownership

The filing reports the end-of-fiscal-year (31 May 2025) equity holdings of Mark Anthony Bottini, Senior Vice President of Sales. No new insider transactions are listed for the period; the document only updates cumulative ownership.

• Direct common-stock holding: 79,360 shares
• Indirect holding: 1,772 shares through the company 401(k) plan
• Employee Stock Purchase Plan (ESPP): 36 shares
• Outstanding stock options: 383,887 options across ten grants with strike prices ranging from $57.24 to $121.63 and expiration dates from July 2026 to July 2034

The absence of reported acquisitions or dispositions suggests that Mr. Bottini neither bought nor sold PAYX shares during FY 2025 under Section 16 reporting rules. His sizable equity and option position continues to align management incentives with shareholder interests, but the filing itself does not signal an operational or financial change for the company.

Insights

Corporate Governance Expert

TL;DR: Routine Form 5; confirms sizeable insider alignment, no trading activity, minimal market impact.

This annual Form 5 discloses only Mr. Bottini’s cumulative holdings. The direct stake of ~79k shares (≈$9 million at $115/share) plus 384k options provides meaningful economic exposure, reinforcing incentive alignment. However, without purchase or sale transactions, it conveys no new sentiment signal. Investors typically view static year-end reports as administrative, with little predictive value for price movement.

Portfolio Manager

TL;DR: Neutral filing; positions unchanged, no liquidity events, not trade-worthy.

The document confirms Mr. Bottini’s long-dated option portfolio and share ownership but introduces no catalysts. Strike prices on newer grants (> $112) imply confidence in long-term appreciation, yet such grants are standard practice. With no Form 4 trades, I consider the filing non-impactful for portfolio decisions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

ABVC BIOPHARMA, INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

00091F304

(CUSIP Number)

Eugene Jiang
Chairman & Chief Business Officer, 44370 Old Warm Springs Blvd.
Fremont, CA, 94538
(510) 668-0881

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/10/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 00091F304

1

Name of reporting person

Eugene Jiang

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,102,265.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,102,265.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

131,159.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

18.50 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(1) The Reporting Person holds 131,159 shares directly; his remaining voting power is a result of certain voting agreements that provide him with sole voting power over an aggregate of 2,141,407 shares held by others, as more fully described herein and sole voting power over 829,699 shares held by YuanGene Corporation.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: ABVC BIOPHARMA, INC.
(c)	Address of Issuer's Principal Executive Offices: 44370 Old Warm Springs Blvd., Fremont, CALIFORNIA , 94538.
Item 2.	Identity and Background
(a)	Eugene Jiang
(b)	44370 Old Warm Springs Blvd., Fremont, CA 94538
(c)	Chairman of the Board of Directors and Chief Business Officer of the Issuer
(d)	N/A
(e)	N/A
(f)	United States
Item 3.	Source and Amount of Funds or Other Consideration
	The Reporting Person has acquired the subject securities in various ways since his original acquisition including but not limited to original issuances from the Issuer and equity compensation under the Issuers Equity Incentive Plan that the Reporting Person received as compensation for employment and Board membership. The Reporting Person also has voting rights to securities that the Reporting Person did not pay for. The Reporting Person holds 131,159 shares directly. He was also appointed as the person with sole voting power over the shares held by YuanGene Corporation, who owns 829,699 shares of the Issuer's Common Stock. As part of the investments made into the Company between June 20, 2025 and July 1, 2025, which resulted in the issuance of an aggregate of 153,850 shares (the "Summer Shares"), the investors entered into a Voting Rights Proxy Agreement, pursuant to which he/she agreed to transfer all of his/her voting rights over his/her share of the Summer Shares to the Reporting Person for the maximum time permitted by law.
Item 4.	Purpose of Transaction
	Certain of the Issuer's shareholders sought to grant the Reporting Person voting rights with respect to such shareholder's shares.
Item 5.	Interest in Securities of the Issuer
(a)	The Reporting Person has voting control over 3,102,265shares of Common Stock of the Issuer, which represents 18.50% of the outstanding and issued Common Stock, based on 16,773,261 shares of the Issuer's Common Stock issued and outstanding as of June 27, 2025.
(b)	Please refer to rows 7-12 on the cover page.
(c)	Between June 20, 2025 and July 1, 2025, the Issuer sold an aggregate of 153,850shares (the "Shares") of its Common Stock to Non-U.S. Persons (as defined in Regulation S under the Securities Act) (the "Investors"), pursuant to Regulation S thereunder ("Regulation S"). The Company received aggregate gross proceeds of $200,000. Each of the Investors entered into a Voting Rights Proxy Agreement, pursuant to which he/she agreed to transfer all of his/her voting rights to the Reporting Person for the maximum time permitted by law.
(d)	The Investors have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.
(e)	N/A
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Other than as described in this Schedule, to the knowledge of the Reporting Person, there are no contracts, arrangements, understandings, or relationships (legal or otherwise) between the Reporting Person and any other persons with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
Item 7.	Material to be Filed as Exhibits.
	(1) Form of Voting Rights Proxy Agreement (incorporated by reference to the Current Report on Form 8-K filed on April 30, 2025).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eugene Jiang

Signature:	/s/ Eugene Jiang
Name/Title:	Eugene Jiang, Chairman & Chief Business Officer
Date:	07/15/2025

FAQ

How many Paychex (PAYX) shares does Mark Anthony Bottini directly own?

He directly owns 79,360 shares of Paychex common stock.

What is the total number of Paychex stock options held by Mr. Bottini?

He holds 383,887 stock options across ten separate grants.

Were any Paychex shares bought or sold by Mr. Bottini during fiscal 2025?

No. The Form 5 lists holdings only; it reports no acquisitions or dispositions for the year.

What is the highest strike price among Mr. Bottini’s outstanding options?

The highest strike price is $121.63 on options expiring 14 July 2034.

Does this Form 5 filing affect Paychex’s financial outlook?

No. The filing is an administrative disclosure of insider holdings and contains no operational or financial guidance for the company.